#covovax price

[bengalbytes]

Novavax vaccine efficacy data promising, encouraging: Govt

Novavax vaccine efficacy data promising, encouraging: Govt

Image Source : AP Novavax vaccine efficacy data promising, encouraging: Govt The government Tuesday said the efficacy data of Novavax vaccine against COVID-19 is promising and encouraging and its clinical trials are in an advanced stage of completion in India. Addressing a press conference, NITI Aayog Member (Health) V K Paul said the data available in public domain also indicates the vaccine is…

[aksarnews]

Pharma Stocks Gain After Centre Approves Use Of COVID Pill Molnupiravir

Pharma Stocks Gain After Centre Approves Use Of COVID Pill Molnupiravir

The government also approved two ne vaccines Corbevax and Covovax yesterday Pharmaceutical shares such as Cipla, Dr Reddy’s Laboratories, Torrent Pharmaceuticals, Sun Pharmaceutical Industries gained around two per cent each on Wednesday, December 29, after the Drug Controller General of India (DCGI) approved the emergency use of anti-viral drug – Molnupiravir in the country. to fight against…

[everythingshouldbereality]

Novavax Vaccine: Hope to launch Covovax by June 2021, says Adar Poonawalla

Novavax Vaccine: Hope to launch Covovax by June 2021, says Adar Poonawalla

Image Source : PTI After Covishield , Serum Institute hope to launch COVOVAX vaccine by June, says Adar Poonawalla After successfully launching coronavirus vaccine COVISHIELD, the Serum Institute of India (SII) has applied to India’s drugs controller for permission to conduct small domestic trial in India for Novavax’s Coronavirus disease (Covid-19) vaccine candidate ‘COVOVAX’, SII chief Adar…

[phgq]

Sugar industry leaders eyeing procurement of Covovax vaccines

#PHnews: Sugar industry leaders eyeing procurement of Covovax vaccines

BACOLOD CITY – Stakeholders of the sugar industry are negotiating for the procurement of Covovax, a vaccine developed by Novavax Inc. and distributed locally by Faberco Life Sciences Inc., to initiate a mass inoculation program against coronavirus disease 2019 (Covid-19).

In a statement on Thursday, Sugar Regulatory Administration (SRA) Board Member Emilio Bernardino Yulo said SRA officials along with millers, sugar federations, planters, and local government units (LGUs) in sugar-producing areas are in talks with the Covovax distributors.

They are working on how to directly secure slots from the 30 million doses initially reserved for the Philippine government, he added.

“We are now in exploratory talks with the makers of Covovax and our next step is to reach out to sugar federations all over the country as well as to LGUs to speed up this process so we can help jumpstart the economy which will also be good for the industry,” Yulo, who hails from Negros Occidental and the representative of the planters’ sector in the SRA Board, said.

He pointed out that the sugar industry needs to support mass vaccination to protect its stakeholders and to allow industries heavily using sugar to also go back to normalcy.

“Tourism, restaurants, schools that are heavily affected by the pandemic are among our biggest consumers and the soonest we can go back to normalcy through mass vaccination, the better it is for the industry and for our economy,” Yulo said.

Sugar industry leaders were briefed by distributors of Covovax in a recent virtual conference facilitated by Yulo, fellow SRA Board Member Roland Beltran, who represents the millers’ sector, and multi-sectoral alliance Tatak Kalamay.

“Tatak Kalamay, which has a membership in almost all sugar-producing areas, will be mobilized in the vaccination campaign,” Yulo said.

He added that it is interesting that in the clinical trials for Covovax, the special group of the immunocompromised group and the older population from 65-84 years old has been included.

“It is also reasonably priced with an indicative price plus estimated logistical costs to Bacolod at PHP1,400 for two doses,” he added.

Vaccine distributors are looking at a mass rollout by the third quarter of the year, but are hoping that they will be able to distribute Covovax by June or July in the Philippines, Yulo said.

Some 1.2 billion doses of Covovax are expected to be produced by the Serum Institute of India, the world’s largest vaccine manufacturer. (PNA)

  ***

References:

* Philippine News Agency. "Sugar industry leaders eyeing procurement of Covovax vaccines." Philippine News Agency. https://www.pna.gov.ph/articles/1132537 (accessed March 04, 2021 at 10:02PM UTC+14).

* Philippine News Agency. "Sugar industry leaders eyeing procurement of Covovax vaccines." Archive Today. https://archive.ph/?run=1&url=https://www.pna.gov.ph/articles/1132537 (archived).

[phgq]

PH signs deal to secure 30M doses of Covovax

#PHnews: PH signs deal to secure 30M doses of Covovax

MANILA – The Philippine government, represented by vaccine czar Secretary Carlito Galvez Jr., Serum Institute of India (SII), and Faberco Life Sciences, Inc. signed a term sheet on Saturday to secure 30 million doses of Covid-19 vaccine Covovax that will be available starting third quarter of this year.

“This is a significant milestone in relations between India and the Philippines. It shows that we don’t have to look far beyond Philippine shores to find friends who are willing to help each other out,” said Kishore Hemlani, founder of Faberco Life Sciences Inc., SII’s Philippine partner, after the signing with Galvez.

SII, the world’s largest vaccine manufacturer, partnered with Novavax, a US-based biotechnology company for the development and commercialization of the Covovax vaccine.

The vaccine has the recombinant coronavirus spike protein nanoparticle and a Novavax-patented Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

Covovax is in third-stage trials and expected to be approved for use by international regulators. 

“The vaccine will be used to vaccinate 15 million vulnerable and poor Filipinos. The vaccine is stable at 2°C to 8°C, the standard temperature that is within the existing cold chain system in the Philippines, thus allowing its distribution to the remotest barangays,” said Faberco Life Sciences medical director Luningning Villa.

The candidate vaccine is thoroughly evaluated in different geographies, various age groups, groups that are most affected by Covid-19, including people living with HIV, and racial and ethnic minorities.

The clinical trials involve a sizeable population of around 50,000 subjects to ensure extreme robust clinical data prior to approval by relevant regulatory bodies including the World Health Organization.

The vaccine underwent the initial phase of the clinical trials in Australia, South Africa and India.

Phase three trial is currently carried out in the United Kingdom with 15,000 subjects and also ongoing in the United States and Mexico with 30,000 subjects.

The price of the vaccine is expected to be finalized soon between the government and SII, which is noted for providing effective, safe and affordable vaccines across the globe through the decades.

Faberco Life Sciences, Inc., is also SII’s partner for key programs in the country such as the inactivated polio vaccine, rotavirus vaccine, pneumococcal conjugate vaccine, aside from the Covid-19 vaccine. (PR)

***

References:

* Philippine News Agency. "PH signs deal to secure 30M doses of Covovax." Philippine News Agency. https://www.pna.gov.ph/articles/1126945 (accessed January 11, 2021 at 07:19AM UTC+14).

* Philippine News Agency. "PH signs deal to secure 30M doses of Covovax." Archive Today. https://archive.ph/?run=1&url=https://www.pna.gov.ph/articles/1126945 (archived).